Evidence map›Paper›PMID 41312384›Full record

ArticleiScience2025

SEL1L confers reduced EMT and drug resistance to breast cancer cells by promoting Shh degradation.

Hao Zhou, Jie Wang, Xu Wang, Zhaoji Guo, Yan Chen, Erli Gao, Jie Sun, Siying Zhou, Xinyi Guan, Yuxin Wu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hao ZhouDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Jie WangDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Xu WangDepartment of Anesthesiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.
Zhaoji GuoDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Yan ChenDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Erli GaoDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Jie SunDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Siying ZhouDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Xinyi GuanDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Yuxin WuDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Zhe ZhaoCAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, Jiangsu 215123, China.
Yuting KuangDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression of SEL1L (suppressor/enhancer of Lin-12-like) is found to be downregulated in clinical breast cancer (BRC) and lymph node metastasis tissues, as well as in carboplatin-resistant BRC cell lines. In this study, reduced SEL1L expression was linked to poor prognosis in BRC, while silencing SEL1L in BRC cells led to increased epithelial-mesenchymal transition (EMT) and metastasis. Furthermore, SEL1L sensitized cancer cells to the anti-cancer drug carboplatin, leading to enhanced apoptosis in both

Indexed as

Biological sciencesCancer

Identifiers

PMID41312384
PMCPMC12648483

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.